Last reviewed · How we verify
NCT06647641
The CurePSP Genetics Program
trial testing Whole genome sequencing will be performed at the NIH in PSP in 1,000 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 8 October 2024 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Whole genome sequencing will be performed at the NIH
Conditions studied
- PSP — all drugs for PSP →
- PSP - Progressive Supranuclear Palsy — all drugs for PSP - Progressive Supranuclear Palsy →
- Corticobasal Syndrome — all drugs for Corticobasal Syndrome →
- Corticobasal Syndrome(CBS) — all drugs for Corticobasal Syndrome(CBS) →
Sponsor
Massachusetts General Hospital
Who can join
35 and older, any sex, with PSP or PSP - Progressive Supranuclear Palsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06647641
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PSP
Currently open trials in the same condition.
- NCT07316413 — Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration · NA · recruiting
- NCT06122662 — AMX0035 and Progressive Supranuclear Palsy · Phase 2, PHASE3 · active not recruiting
- NCT05956834 — A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes · active not recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06647641 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06647641.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing